| __timestamp | BioCryst Pharmaceuticals, Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 15823000 |
| Thursday, January 1, 2015 | 72758000 | 17026000 |
| Friday, January 1, 2016 | 61008000 | 15941000 |
| Sunday, January 1, 2017 | 66962000 | 18938000 |
| Monday, January 1, 2018 | 84888000 | 58124000 |
| Tuesday, January 1, 2019 | 107068000 | 83837000 |
| Wednesday, January 1, 2020 | 122964000 | 35882000 |
| Friday, January 1, 2021 | 208808000 | 64542000 |
| Saturday, January 1, 2022 | 253297000 | 67995000 |
| Sunday, January 1, 2023 | 216566000 | 80118000 |
Cracking the code
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, BioCryst Pharmaceuticals, Inc. has consistently outpaced CymaBay Therapeutics, Inc. in R&D investment. From 2014 to 2023, BioCryst's R&D expenses surged by approximately 318%, peaking in 2022. In contrast, CymaBay's R&D spending grew by about 406% during the same period, albeit from a smaller base.
BioCryst's strategic focus on R&D is evident, with expenditures reaching nearly 2.5 times that of CymaBay in 2022. This trend underscores BioCryst's aggressive pursuit of innovation, particularly in the development of novel therapeutics. Meanwhile, CymaBay's steady increase in R&D spending highlights its growing commitment to advancing its pipeline. As the biotech landscape evolves, these investments will likely play a crucial role in shaping the future of both companies.
Comparing Innovation Spending: Novo Nordisk A/S and CymaBay Therapeutics, Inc.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs CymaBay Therapeutics, Inc.
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Viatris Inc. vs CymaBay Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and CymaBay Therapeutics, Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Opthea Limited and CymaBay Therapeutics, Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.